Trademark Overview
On Tuesday, August 8, 2023, a trademark application was filed for VYRIAD with the United States Patent and Trademark Office. The USPTO has given the VYRIAD trademark a serial number of 98122765. The federal status of this trademark filing is OPPOSITION PENDING as of Thursday, November 7, 2024. This trademark is owned by Vyriad, Inc.. The VYRIAD trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:
Pharmaceuticals, namely, bio-pharmaceuticals for the treatment of cancer; stem cells for medical use for the treatment of cancer,
cardiovascular diseases, and heritable genetic diseases; medicinal preparations for use in oncology; pharmaceutical preparations
for the treatment of immune system related diseases and disorders, namely, cancer and cardiovascular diseases and heritable
genetic diseases; pharmaceutical preparations for treatment of genetic and heritable genetic diseases; cellular pharmaceutical
preparations for use in oncology and cardio-vascular diseases; living tissue in the nature of chimeric antigen receptor (CAR-T)
cells for medical use for the treatment of cancer, cardiovascular diseases, and heritable genetic diseases; pharmaceutical
preparations for use in oncology; all of the foregoing to exclude infectious diseases
Medical and scientific research and development in the fields of cancer treatment and oncolytic virotherapy; research and
development of bio-pharmaceuticals for the treatment of cancer, cardiovascular diseases, and heritable genetic diseases; medical
and scientific research in the fields of genetics and oncology; research and development of technology in the fields of stem cells
and stem cell therapy for the treatment of cancer, cardiovascular diseases, and heritable genetic diseases; development of
genetic therapies and chimeric antigen receptor cell (CAR-T) cell therapies for the treatment of cancer, cardiovascular diseases,
and heritable genetic diseases; scientific research and development of cell therapies, namely, chimeric antigen receptor T-cells
(CAR-T) to cure solid tumor cancers and other cancers; medical and scientific research services in the fields of genetics, cell
therapy, oncology, immuno-oncology; all of the foregoing to exclude infectious diseases
